145 related articles for article (PubMed ID: 12175773)
1. Andrew Gearing. Interview by Suzanne Berry.
Berry S
Trends Biotechnol; 2002 Sep; 20(9):404-5. PubMed ID: 12175773
[No Abstract] [Full Text] [Related]
2. Sunbaked biotechnology in Australia.
Littlejohn T
Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
[No Abstract] [Full Text] [Related]
3. China's biotech experiments.
Hepeng J
Nat Biotechnol; 2005 Dec; 23(12):1472-3. PubMed ID: 16421994
[No Abstract] [Full Text] [Related]
4. Divining the path to a successful European exit.
Buch HK; Gustafsson AC; Drvota V; Sundberg CJ
Nat Biotechnol; 2011 Mar; 29(3):205-7. PubMed ID: 21510008
[No Abstract] [Full Text] [Related]
5. Michigan's next wave of biopharmaceutical entrepreneurship.
Kerppola R; van de Walle M; Surine S
Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
[No Abstract] [Full Text] [Related]
6. Calling for entrepreneurs: London.
Smaglik P
Nat Biotechnol; 2002 Dec; 20(12):1281-2. PubMed ID: 12454679
[No Abstract] [Full Text] [Related]
7. How Indian biotech is driving innovation.
Nogrady B
Nature; 2018 Dec; 564(7735):S53-S55. PubMed ID: 30542184
[No Abstract] [Full Text] [Related]
8. Bioentrepreneurship around the world.
Persidis A
Nat Biotechnol; 1998 May; 16 Suppl():3-4. PubMed ID: 9591247
[No Abstract] [Full Text] [Related]
9. Big pharma wants you.
Mack GS
Nat Biotechnol; 2006 Nov; 24(11):1317-9. PubMed ID: 17162751
[TBL] [Abstract][Full Text] [Related]
10. Japanese firms broaden investment focus to early biotech.
Louët S; Sipp D
Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
[No Abstract] [Full Text] [Related]
11. Biologist aims to ease the pain for entrepreneurs.
Gewin V
Nature; 2006 Apr; 440(7085):738-9. PubMed ID: 16598227
[No Abstract] [Full Text] [Related]
12. Who took the tech out of biotech?
Silverman E
Nat Biotechnol; 2006 Mar; 24(3):255-6. PubMed ID: 16525373
[No Abstract] [Full Text] [Related]
13. Private company profiles.
Nat Biotechnol; 2003 Jul; 21 Suppl():BE23-8. PubMed ID: 12874973
[No Abstract] [Full Text] [Related]
14. Building for an exit (or not).
Gunning TG
Nat Biotechnol; 2008 Sep; 26(9):971-3. PubMed ID: 18792427
[TBL] [Abstract][Full Text] [Related]
15. Value creation and sharing among universities, biotechnology and pharma.
Edwards MG; Murray F; Yu R
Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
[No Abstract] [Full Text] [Related]
16. Innovation in Manchester.
Smith M
Nat Biotechnol; 2002 Jul; 20 Suppl():BE24-6. PubMed ID: 12089581
[No Abstract] [Full Text] [Related]
17. Q&A: Horst Domdey.
Wald C
Nature; 2016 May; 533(7601):S30-1. PubMed ID: 27144606
[No Abstract] [Full Text] [Related]
18. Spin-offs versus start-ups as business models in biotechnology.
Persidis A; De Rubertis F
Nat Biotechnol; 2000 May; 18(5):570-1. PubMed ID: 10802637
[No Abstract] [Full Text] [Related]
19. Biotech booms in China.
Ellis S
Nature; 2018 Jan; 553(7688):S19-S22. PubMed ID: 29345681
[No Abstract] [Full Text] [Related]
20. Marketing biotechnology with a Gallic flair.
Jouanneau AC
Nat Biotechnol; 2003 Jul; 21 Suppl():BE36-7. PubMed ID: 12874977
[No Abstract] [Full Text] [Related]
[Next] [New Search]
